SUBSCRIBE
SUBSCRIBE

Ultragenyx Pharmaceutical Inc.

NEWS
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Deals
Bay Area’s Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics
September 18, 2017
 · 
3 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
Bay Area’s Ultragenyx Tanks as Seizure Drug Flunks Phase II Test
March 23, 2017
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
10 Biotech Stocks that Could Blow Up in Q3
July 6, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
Nine Bay Area Biotechs Vie to be the “Next Genentech”
May 24, 2016
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Arcturus Therapeutics Stands to Collect Up to $1.66 Billion from Rare Disease Pact with Ultragenyx
October 29, 2015
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - August 18, 2023
August 18, 2023
 · 
1 min read
Business
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
August 3, 2023
 · 
15 min read
Drug Development
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
July 31, 2023
 · 
6 min read
Business
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
July 27, 2023
 · 
1 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 18, 2023
July 18, 2023
 · 
1 min read
Business
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
July 12, 2023
 · 
3 min read
Drug Development
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
July 6, 2023
 · 
8 min read
Genetown
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
June 21, 2023
 · 
3 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 20, 2023
June 20, 2023
 · 
1 min read
Biotech Bay
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 7, 2023
 · 
1 min read
Load More